MARKET

MEIP

MEIP

MEI Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.420
0.000
0.00%
Opening 10:54 04/23 EDT
OPEN
3.470
PREV CLOSE
3.420
HIGH
3.490
LOW
3.400
VOLUME
46.77K
TURNOVER
--
52 WEEK HIGH
4.575
52 WEEK LOW
2.290
MARKET CAP
384.85M
P/E (TTM)
-9.3930
1D
5D
1M
3M
1Y
5Y
Brookline Capital Markets Keeps a Buy Rating on MEI Pharma (MEIP)
Brookline Capital Markets analyst Leah R. Cann maintained a Buy rating on MEI Pharma (MEIP) on April 13 and set a price target of $11.50. The company's
SmarterAnalyst · 6d ago
Histone Deacetylase (Hdac) Inhibitors Market 2021 Trends, Size, Growth Insight, Share, Emerging Technologies, Share, Competitive, Regional, And Global Forecast To 2026
Apr 16, 2021 (The Expresswire) -- Global "Histone Deacetylase (Hdac) Inhibitors Market"(2021-2026) provides an all-inclusive assessment of the market and...
The Express Wire · 04/16 07:26
Analysts Offer Insights on Healthcare Companies: MEI Pharma (MEIP) and NovoCure (NVCR)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on MEI Pharma (MEIP) and NovoCure (NVCR). MEI Pharma (MEIP) Alliance Global
SmarterAnalyst · 04/13 18:15
BRIEF-Mei Pharma And Kyowa Kirin Announce Completion Of Patient Enrollment In Follicular Lymphoma Primary Efficacy Population Of Global Phase 2 Tidal Study
reuters.com · 04/13 11:13
MEI Pharma and Kyowa Kirin Announce Completion of Patient Enrollment in Follicular Lymphoma Primary Efficacy Population of Global Phase 2 TIDAL Study Intended to Support Potential Accelerated Approval Application from U.S. Food and Drug Administration (FDA)
SAN DIEGO, April 13, 2021 /PRNewswire via COMTEX/ -- SAN DIEGO, April 13, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical...
PR Newswire - PRF · 04/13 11:00
MEI Pharma Presents Positive Preclinical Data For Cancer Drug Voruciclib
MEI Pharma announced positive preclinical data for its orally administered drug, voruciclib. Voruciclib blocks CDK9, a cyclin-dependent kinase (CDK) inhibitor and hinders growth of KRAS mutant cancers. MEI Pharma’s (MEIP) President and CEO, Daniel P. Gold,...
SmarterAnalyst · 04/12 17:53
MEI Pharma Saturday Morning Announced Preclinical Data Showing Ability Of Voruciclib to Regulate MYC, Synergize With KRAS Inhibitors At Ammerican Assocation For Cancer Research Meeting Apr. 13, 2021
MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced preclinical data demonstrating that voruciclib, an orally administered
Benzinga · 04/12 14:11
Histone Deacetylase 2 Market Professional Survey, Growth, Shares, Opportunities and Forecast to 2027
Apr 12, 2021 (Market Insight Reports) -- The latest report as Histone Deacetylase 2 Market acknowledges Size, Application Segment, Type, Regional Outlook,...
Market Insight Reports · 04/12 09:39
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MEIP. Analyze the recent business situations of MEI Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MEIP stock price target is 9.67 with a high estimate of 13.00 and a low estimate of 5.50.
EPS
Institutional Holdings
Institutions: 149
Institutional Holdings: 87.70M
% Owned: 77.94%
Shares Outstanding: 112.53M
TypeInstitutionsShares
Increased
50
3.06M
New
16
10.49M
Decreased
24
2.21M
Sold Out
9
1.85M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.22%
Pharmaceuticals & Medical Research
+0.49%
Key Executives
Non-Executive Chairman/Independent Director
Christine White
Chief Executive Officer/President/Director
Daniel Gold
Chief Financial Officer/Secretary
Brian Drazba
Chief Operating Officer/General Counsel
David Urso
Senior Vice President/Director of Marketing
Brian Powl
Other
Robert Mass
Independent Director
Charles Baltic
Independent Director
Kevan Clemens
Independent Director
Cheryl Cohen
Independent Director
Frederick Driscoll
Independent Director
Nicholas Glover
Independent Director
Tamar Howson
Independent Director
Thomas Reynolds
No Data
  • All
  • Financials
  • Insiders
More
About MEIP
MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and ME-401. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. ME-401 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.

Webull offers kinds of MEI Pharma Inc stock information, including NASDAQ:MEIP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MEIP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MEIP stock methods without spending real money on the virtual paper trading platform.